login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CORCEPT THERAPEUTICS INC (CORT) Stock News
USA
- NASDAQ:CORT -
US2183521028
-
Common Stock
78.69
USD
-0.78 (-0.98%)
Last: 10/17/2025, 8:04:00 PM
78.01
USD
-0.68 (-0.86%)
After Hours:
10/17/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CORT Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Corcept Therapeutics Incorporated
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
3 months ago - By: Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
3 months ago - By: Benzinga
- Mentions:
BSAC
BGC
RMNI
MTZ
...
Earnings Scheduled For July 31, 2025
18 days ago - By: Zacks Investment Research
- Mentions:
MRK
Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?
a month ago - By: Corcept Therapeutics Incorporated
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
a month ago - By: Corcept Therapeutics Incorporated
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
2 months ago - By: Zacks Investment Research
- Mentions:
MRK
Can Korlym Drive Corcept's Growth Through the Rest of 2025?
2 months ago - By: Zacks Investment Research
- Mentions:
RIGL
AVDL
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
3 months ago - By: Zacks Investment Research
- Mentions:
CRMD
IMCR
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
3 months ago - By: Zacks Investment Research
- Mentions:
SPRY
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
3 months ago - By: Corcept Therapeutics Incorporated
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
3 months ago - By: Yahoo Finance
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk
3 months ago - By: Yahoo Finance
- Mentions:
GS
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant
Please enable JavaScript to continue using this application.